Brensocatib reduces exacerbations in bronchiectasis: WILLOW study

A novel anti-inflammatory treatment for bronchiectasis that targets neutrophils has shown promising results in a phase 2 trial. In findings presented at ATS 2020 virtual meeting, brensocatib, a reversible inhibitor of dipeptidyl peptidase-1 (DPP1 inhibitor) showed positive effects against bronchietasis exacerbations in patients with non-CF bronchiectasis. Professor James Chalmers, British Lung Foundation Professor of Respiratory ...

Already a member?

Login to keep reading.

© 2021 the limbic